Uppsala, Sweden, 2015-06-04 08:15 CEST (GLOBE NEWSWIRE) --
FOURTH QUARTER February 1 – April 30, 2015
- Consolidated Net sales amounted to TSEK 36 (20)[1]
- Operating income was TSEK -27,791 (-35,239)
- Net income after tax amounted to TSEK -29,622 (-37,790)
- Earnings per share was SEK -0.30 (-0.45)
- Comprehensive income was TSEK -29,622 (-37,790)
THE FISCAL YEAR May 1, 2014 – April 30, 2015
- Consolidated Net sales amounted to TSEK 2,070 (60)
- Operating income was TSEK -107,767 (-98,091)
- Net income after tax amounted to TSEK -117,039 (-105,112)
- Earnings per share was SEK -1.28 (-1.27)
- Comprehensive income was TSEK -117,039 (-105,112)
- Paclical received marketing authorization in Russia.
EVENTS AFTER THE CLOSING DAY
- Changes in Oasmia’s Board of Directors and new CEO appointed
- Authorization for the Board to make decisions on issue of new shares,warrants and convertible debt instruments
CHAIRMAN OF THE BOARD COMMENTS:
”The fourth quarter was very important for Oasmia´s development, as we received our first marketing authorization for Paclical. It is now approved for treatment of ovarian cancer in Russia. We have already start to prepare for the launch in the autumn this year together with our partner in Russia, Pharmasyntez.
We will continue our work with the submission of an application of marketing authorization in the EU for Paclical for treatment of ovarian cancer, the clinical development of Doxophos, Doxophos Vet, Paccal Vet and Docecal, and our collaboration with Baxter for full scale commercial pharmaceutical production”, commented Oasmia´s chairman of the board Julian Aleksov.
[1]The numbers in parentheses show the results from the corresponding period of the previous year
Anders Lundin, CFO
Tel: +46 70 209 63 00
E-mail: anders.lundin@oasmia.com
